Literature DB >> 20007669

Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Nenad Manevski1, Mika Kurkela, Camilla Höglund, Timo Mauriala, Michael H Court, Jari Yli-Kauhaluoma, Moshe Finel.   

Abstract

We have examined the glucuronidation of psilocin, a hallucinogenic indole alkaloid, by the 19 recombinant human UDP-glucuronosyltransferases (UGTs) of subfamilies 1A, 2A, and 2B. The glucuronidation of 4-hydroxyindole, a related indole that lacks the N,N-dimethylaminoethyl side chain, was studied as well. UGT1A10 exhibited the highest psilocin glucuronidation activity, whereas the activities of UGTs 1A9, 1A8, 1A7, and 1A6 were significantly lower. On the other hand, UGT1A6 was by far the most active enzyme mediating 4-hydroxyindole glucuronidation, whereas the activities of UGTs 1A7-1A10 toward 4-hydroxyindole resembled their respective psilocin glucuronidation rates. Psilocin glucuronidation by UGT1A10 followed Michaelis-Menten kinetics in which psilocin is a low-affinity high-turnover substrate (K(m) = 3.8 mM; V(max) = 2.5 nmol/min/mg). The kinetics of psilocin glucuronidation by UGT1A9 was more complex and may be best described by biphasic kinetics with both intermediate (K(m1) = 1.0 mM) and very low affinity components. The glucuronidation of 4-hydroxyindole by UGT1A6 exhibited higher affinity (K(m) = 178 microM) and strong substrate inhibition. Experiments with human liver and intestinal microsomes (HLM and HIM, respectively) revealed similar psilocin glucuronidation activity in both samples, but a much higher 4-hydroxyindole glucuronidation rate was found in HLM versus HIM. The expression levels of UGTs 1A6-1A10 in different tissues were studied by quantitative real-time-PCR, and the results, together with the activity assays findings, suggest that whereas psilocin may be subjected to extensive glucuronidation by UGT1A10 in the small intestine, UGT1A9 is likely the main contributor to its glucuronidation once it has been absorbed into the circulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007669      PMCID: PMC2835393          DOI: 10.1124/dmd.109.031138

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  32 in total

1.  Glucuronidation of apomorphine.

Authors:  R S El-Bachá; S Leclerc; P Netter; J Magdalou; A Minn
Journal:  Life Sci       Date:  2000-08-25       Impact factor: 5.037

2.  Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6.

Authors:  Soundararajan Krishnaswamy; Su X Duan; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

3.  Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.

Authors:  D Turgeon; J S Carrier; E Lévesque; D W Hum; A Bélanger
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

4.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

Review 5.  UDP-glucuronosyltransferases.

Authors:  C D King; G R Rios; M D Green; T R Tephly
Journal:  Curr Drug Metab       Date:  2000-09       Impact factor: 3.731

6.  The detection of psilocin in human urine.

Authors:  A F Grieshaber; K A Moore; B Levine
Journal:  J Forensic Sci       Date:  2001-05       Impact factor: 1.832

7.  Detection of psilocin in body fluids.

Authors:  G Sticht; H Käferstein
Journal:  Forensic Sci Int       Date:  2000-09-11       Impact factor: 2.395

8.  Activation of glucuronidation through reduction of a disulfide bond in rat UDP-glucuronosyltransferase 1A6.

Authors:  Shin-ichi Ikushiro; Yoshikazu Emi; Takashi Iyanagi
Journal:  Biochemistry       Date:  2002-10-22       Impact factor: 3.162

9.  Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3.

Authors:  Nina Sneitz; Michael H Court; Xiuling Zhang; Kaisa Laajanen; Karen K Yee; Pamela Dalton; Xinxin Ding; Moshe Finel
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

10.  Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man.

Authors:  Felix Hasler; Daniel Bourquin; Rudolf Brenneisen; Franz X Vollenweider
Journal:  J Pharm Biomed Anal       Date:  2002-09-05       Impact factor: 3.935

View more
  8 in total

1.  Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite.

Authors:  Miroslav Dostalek; Michael H Court; Suwagmani Hazarika; Fatemeh Akhlaghi
Journal:  Drug Metab Dispos       Date:  2010-12-01       Impact factor: 3.922

Review 2.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

3.  Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.

Authors:  Randall T Brown; Christopher R Nicholas; Nicholas V Cozzi; Michele C Gassman; Karen M Cooper; Daniel Muller; Chantelle D Thomas; Scott J Hetzel; Kelsey M Henriquez; Alexandra S Ribaudo; Paul R Hutson
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

4.  Horizontal gene cluster transfer increased hallucinogenic mushroom diversity.

Authors:  Hannah T Reynolds; Vinod Vijayakumar; Emile Gluck-Thaler; Hailee Brynn Korotkin; Patrick Brandon Matheny; Jason C Slot
Journal:  Evol Lett       Date:  2018-02-27

Review 5.  Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Authors:  Maurizio Coppola; Francesco Bevione; Raffaella Mondola
Journal:  J Xenobiot       Date:  2022-02-07

6.  Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats.

Authors:  Alexandra M Adams; Nicholas A Anas; Abhishek K Sen; Jordan D Hinegardner-Hendricks; Philip J O'Dell; William J Gibbons; Jessica E Flower; Matthew S McMurray; J Andrew Jones
Journal:  Metab Eng Commun       Date:  2022-03-12

Review 7.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

8.  Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives.

Authors:  N Milne; P Thomsen; N Mølgaard Knudsen; P Rubaszka; M Kristensen; I Borodina
Journal:  Metab Eng       Date:  2020-03-26       Impact factor: 9.783

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.